Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegaptanib sodium in Japanese patients with wet AMD
NCT00150202Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2004
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pegaptanib sodium in exudative macular degeneration (2 arms), sponsored by Pfizer. Primary endpoint: Change in Visual Acuity from Baseline at 54 weeks. Started Jul 2004; status: completed.
02
Drugs
pegaptanib sodium
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT00150202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00150202.